2. Search Result
Search Result
Results for "

LFA-1

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

4

Inhibitory Antibodies

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-120628
    BMS-587101

    		Integrin Inflammation/Immunology
    BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1). BMS-587101 has anti-inflammatory effects and can be used for rheumatoid arthritis research [1] .
    BMS-587101
  • HY-110117
    BIRT 377
    2 Publications Verification

    		 Integrin Interleukin Related Inflammation/Immunology
    BIRT 377 is a potent amd orally bioavailable inhibitor of the interaction between intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1), with a Ki of 25.8 nM. BIRT 377 also inhibits the production of IL-2 in vivo. BIRT 377 can be used for researching inflammatory and immune disorders [1].
    BIRT 377
  • HY-19344
    Lifitegrast
    4 Publications Verification

    SAR 1118; SHP-606

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease [1].
    Lifitegrast
  • HY-19344A
    Lifitegrast sodium
    4 Publications Verification

    SAR 1118 sodium; SHP-606 sodium

    		 Integrin Inflammation/Immunology
    Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease [1].
    Lifitegrast sodium
  • HY-107587
    A-286982
    2 Publications Verification

    		 Integrin Inflammation/Immunology
    A-286982 is a potent and allosteric LFA-1/ICAM-1 interaction inhibitor with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding and LFA-1-mediated cellular adhesion assay, respectively [1] .
    A-286982
  • HY-P9947
    Efalizumab

    		Integrin Others
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research [1].
    Efalizumab
  • HY-124040
    BI-1950

    		Integrin Inflammation/Immunology
    BI-1950 is a highly potent lymphocyte function associated antigen-1 (LFA-1) inhibitor. LFA-1 is an essential component in normal immune system function and a target for agent discovery [1].
    BI-1950
  • HY-122192
    ICAM-1988

    		Others Inflammation/Immunology
    ICAM-1988 is a small molecule lymphocyte function-associated antigen-1 (LFA-1) antagonist that disrupts the LFA-1/ICAM-1 interaction and has anti-inflammatory activity [1].
    ICAM-1988
  • HY-139202
    XVA143

    		Integrin Inflammation/Immunology
    XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo [1].
    XVA143
  • HY-19344R
    Lifitegrast (Standard)

    		Integrin Inflammation/Immunology
    Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease [1].
    Lifitegrast (Standard)
  • HY-19151
    Fuzapladib

    IS-741

    		 Integrin Phospholipase Inflammation/Immunology
    Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site [1] .
    Fuzapladib
  • HY-19151A
    Fuzapladib sodium

    IS-741 sodium

    		 Integrin Phospholipase Inflammation/Immunology
    Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site [1] .
    Fuzapladib sodium
  • HY-19151B
    Fuzapladib potassium

    IS-741 potassium

    		 Integrin Phospholipase Inflammation/Immunology
    Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site [1] .
    Fuzapladib potassium
  • HY-19151C
    Fuzapladib calcium

    IS-741 calcium

    		 Integrin Phospholipase Inflammation/Immunology
    Fuzapladib calcium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib calcium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib calcium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site [1] .
    Fuzapladib calcium
  • HY-110086
    RWJ 50271

    		Integrin Inflammation/Immunology
    RWJ 50271 is an selective and orally active inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells). RWJ 50271 inhibits LFA-1/ICAM-1-mediated cell adhesion [1].
    RWJ 50271
  • HY-10596
    BMS-688521
    1 Publications Verification

    		 Integrin Inflammation/Immunology
    BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model [1].
    BMS-688521

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: